PRIMARY STUDY
Cannabinoids in rheumatology: Friend, foe or a bystander?
Key Findings: This review finds that cannabinoid use in rheumatologic conditions is beneficial based on patient reports, however, the evidence of adverse events and drug-drug interactions are concerning and should be evaluated further by randomized controlled trials.
Type of Study: Meta-analysis
Study Sample Size: 613
Study Result: Inconclusive
Research Location(s): Georgia, India, United Kingdom
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, O-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified), Endocannabinoid (unspecified), Pharma THC, Pharma THC:CBD
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, PPAR - Alpha, PPAR - Gamma
Ligands Studied: Pro-inflammatory cytokines, Glucocorticoid
Citation: Jain N and Moorthy A. Cannabinoids in rheumatology: Friend, foe or a bystander?. Musculoskeletal Care. 2022; 20:416-428. doi: 10.1002/msc.1636
Authors: Jain N, Moorthy A
